52057-89-3 Usage
Uses
Used in Pharmaceutical Applications:
5-Isobutyl-[1,3,4]thiadiazol-2-ylamine is used as a building block in organic synthesis for the preparation of various derivatives with potential biological activities. Its unique structure and properties contribute to the development of new pharmaceutical compounds with therapeutic benefits.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 5-isobutyl-[1,3,4]thiadiazol-2-ylamine is utilized for its potential to enhance the properties of existing drugs or to develop new therapeutic agents. Its diverse range of biological activities makes it a valuable component in the design and synthesis of novel pharmaceutical compounds.
Used in Agrochemical Development:
5-Isobutyl-[1,3,4]thiadiazol-2-ylamine may have potential applications in the development of new agrochemicals. Its unique properties can be harnessed to create innovative solutions for agricultural challenges, such as pest control and crop protection.
Used in Materials Science:
In materials science, 5-isobutyl-[1,3,4]thiadiazol-2-ylamine can be explored for its potential to contribute to the development of new materials with specific properties. Its unique structure and properties make it a promising candidate for further research and development in this field.
Check Digit Verification of cas no
The CAS Registry Mumber 52057-89-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,2,0,5 and 7 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 52057-89:
(7*5)+(6*2)+(5*0)+(4*5)+(3*7)+(2*8)+(1*9)=113
113 % 10 = 3
So 52057-89-3 is a valid CAS Registry Number.
InChI:InChI=1/C6H11N3S/c1-4(2)3-5-8-9-6(7)10-5/h4H,3H2,1-2H3,(H2,7,9)
52057-89-3Relevant academic research and scientific papers
Novel selective inhibitors of neutral endopeptidase for the treatment of female sexual arousal disorder. Synthesis and activity of functionalized glutaramides
Pryde, David C.,Maw, Graham N.,Planken, Simon,Platts, Michelle Y.,Sanderson, Vivienne,Corless, Martin,Stobie, Alan,Barber, Christopher G.,Russell, Rachel,Foster, Laura,Barker, Laura,Wayman, Christopher,Van Der Graaf, Piet,Stacey, Peter,Morren, Debbie,Kohl, Christopher,Beaumont, Kevin,Coggon, Sara,Tute, Michael
, p. 4409 - 4424 (2007/10/03)
Female sexual arousal disorder (FSAD) is a highly prevalent sexual disorder affecting up to 40% of women. We describe herein our efforts to identify a selective neutral endopeptidase (NEP) inhibitor as a potential treatment for FSAD. The rationale for this approach, together with a description of the medicinal chemistry strategy, lead compounds, and SAR investigations are detailed. In particular, the strategy of starting with the clinically precedented selective NEP inhibitor, Candoxatrilat, and targeting low molecular weight and relatively polar mono-carboxylic acids is described. This led ultimately to the prototype development candidate R-13, for which detailed pharmacology and pharmacokinetic parameters are presented.
